Johnson & Johnson (JNJ) 8-K Regulation FD Disclosure

Exhibit 99.1

Reformatted Sales Schedules

	Johnson & Johnson
	$MM
		2011
		Q1		Q2	Q3	Q4	Full Year
PHARMACEUTICAL SEGMENT (1)
IMMUNOLOGY
US		$	1,436	1,524	1,390	1,401	5,751
Intl		144		131	377	395	1,047
WW		1,580		1,655	1,767	1,796	6,798
	REMICADE
	US	788		836	876	776	3,276
	US Exports(2)	490		527	343	437	1,797
	Intl	7		8	189	215	419
	WW	1,285		1,371	1,408	1,428	5,492
	SIMPONI
	US	53		61	59	62	235
	Intl	42		6	70	57	175
	WW	95		67	129	119	410
	STELARA
	US	105		100	112	126	443
	Intl	61		76	77	81	295
	WW	166		176	189	207	738
	OTHER IMMUNOLOGY
	US	—		—	—	—	—
	Intl	34		41	41	42	158
	WW	34		41	41	42	158
See footnotes at end of schedule

	Johnson & Johnson
	$MM
		2011
		Q1		Q2	Q3	Q4		Full Year
PHARMACEUTICAL SEGMENT(1) (continued)
INFECTIOUS DISEASES
US		$	624	351	216	210		1,401
Intl		307		477	498	506		1,788
WW		931		828	714	716		3,189
	INTELENCE
	US	38		38	42	45		163
	Intl	31		41	41	38		151
	WW	69		79	83	83		314
	LEVAQUIN/FLOXIN
	US	422		149	14	(6	)	579
	Intl	12		10	11	11		44
	WW	434		159	25	5		623
	PREZISTA
	US	126		128	132	143		529
	Intl	140		185	184	173		682
	WW	266		313	316	316		1,211
	OTHER INFECTIOUS DISEASES
	US	38		36	28	28		130
	Intl	124		241	262	284		911
	WW	162		277	290	312		1,041
	See footnotes at end of schedule

	Johnson & Johnson
	$MM
		2011
		Q1		Q2	Q3	Q4	Full Year
PHARMACEUTICAL SEGMENT(1) (continued)
NEUROSCIENCE
US		$	688	684	634	611	2,617
Intl		1,057		1,096	1,050	1,128	4,331
WW		1,745		1,780	1,684	1,739	6,948
	CONCERTA/METHYLPHENIDATE
	US	254		234	179	155	822
	Intl	108		115	104	119	446
	WW	362		349	283	274	1,268
	INVEGA
	US	69		76	74	66	285
	Intl	51		52	52	59	214
	WW	120		128	126	125	499
	INVEGA SUSTENNA
	US	65		70	85	99	319
	Intl	—		7	16	36	59
	WW	65		77	101	135	378
	RISPERDAL CONSTA
	US	114		110	111	108	443
	Intl	290		294	279	277	1,140
	WW	404		404	390	385	1,583
	OTHER NEUROSCIENCE
	US	186		194	185	183	748
	Intl	608		628	599	637	2,472
	WW	794		822	784	820	3,220
	See footnotes at end of schedule

	Johnson & Johnson
	$MM
		2011
		Q1		Q2	Q3	Q4	Full Year
PHARMACEUTICAL SEGMENT(1) (continued)
ONCOLOGY
US		$	64	93	79	95	331
Intl		375		459	415	468	1,717
WW		439		552	494	563	2,048
	DOXIL/CAELYX
	US	64		56	10	10	140
	Intl	75		82	76	29	262
	WW	139		138	86	39	402
	VELCADE
	US	—		—	—	—	—
	Intl	280		347	295	352	1,274
	WW	280		347	295	352	1,274
	ZYTIGA
	US	—		37	69	85	191
	Intl	5		12	26	67	110
	WW	5		49	95	152	301
	OTHER ONCOLOGY
	US	—		—	—	—	—
	Intl	15		18	18	20	71
	WW	15		18	18	20	71
TOTAL OTHER
US		579		587	550	570	2,286
Intl		785		831	773	710	3,099
WW		1,364		1,418	1,323	1,280	5,385
	ACIPHEX/PARIET
	US	109		101	94	110	414
	Intl	130		146	141	144	561
	WW	239		247	235	254	975
	PROCRIT/EPREX
	US	190		257	176	191	814
	Intl	207		218	207	177	809
	WW	397		475	383	368	1,623
	OTHER
	US	280		229	280	269	1,058
	Intl	448		467	425	389	1,729
	WW	728		696	705	658	2,787
TOTAL PHARMACEUTICAL
US		3,391		3,239	2,869	2,887	12,386
Intl		2,668		2,994	3,113	3,207	11,982
WW		$	6,059	6,233	5,982	6,094	24,368
See footnotes at end of schedule

Johnson & Johnson
$MM
	2011
	Q1		Q2	Q3	Q4	Full Year
MEDICAL DEVICES AND DIAGNOSTICS(1)
CARDIOVASCULAR CARE
US	$	242	210	198	191	841
Intl	393		377	328	349	1,447
WW	635		587	526	540	2,288
DIABETES CARE
US	311		333	338	330	1,312
Intl	326		348	326	340	1,340
WW	637		681	664	670	2,652
DIAGNOSTICS(3)
US	265		281	265	280	1,091
Intl	256		269	274	274	1,073
WW	521		550	539	554	2,164
GENERAL SURGERY(4)
US	596		621	609	639	2,465
Intl	1,025		1,079	1,013	1,055	4,172
WW	1,621		1,700	1,622	1,694	6,637
INFECTION PREVENTION/OTHER(5)
US	95		98	90	94	377
Intl	121		134	130	144	529
WW	216		232	220	238	906
ORTHOPAEDICS(6)
US	811		770	737	775	3,093
Intl	692		699	647	678	2,716
WW	1,503		1,469	1,384	1,453	5,809
SPECIALTY SURGERY(7)
US	296		311	292	327	1,226
Intl	281		309	284	307	1,181
WW	577		620	576	634	2,407
VISION CARE
US	256		245	251	214	966
Intl	466		487	501	496	1,950
WW	722		732	752	710	2,916
TOTAL MEDICAL DEVICES AND DIAGNOSTICS
US	2,872		2,869	2,780	2,850	11,371
Intl	3,560		3,702	3,503	3,643	14,408
WW	$	6,432	6,571	6,283	6,493	25,779
(1) Select areas (unaudited)
(2) Reported as U.S. sales
(3) Previously Ortho-Clinical Diagnostics
(4) General Surgery includes the endo-mechanical, hernia, sutures and women’s health businesses previously part of Ethicon and Ethicon Endo-Surgery
(5) Infection Prevention/Other includes the Advanced Sterilization Products business previously part of Ethicon Endo-Surgery
(6) Previously DePuy
(7) Specialty Surgery includes the Acclarent, biosurgery, energy, Mentor and SterilMed businesses previously part of Ethicon and Ethicon Endo-Surgery